Marinomed Biotech AG

WBAG:MARI Stock Report

Market Cap: €22.4m

Marinomed Biotech Management

Management criteria checks 2/4

Marinomed Biotech's CEO is Andreas Grassauer, appointed in Apr 2006, has a tenure of 19.08 years. directly owns 7.4% of the company’s shares, worth €1.66M. The average tenure of the management team and the board of directors is 19.1 years and 4.7 years respectively.

Key information

Andreas Grassauer

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure19.1yrs
CEO ownership7.4%
Management average tenure19.1yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

A Look At The Fair Value Of Marinomed Biotech AG (VIE:MARI)

May 25
A Look At The Fair Value Of Marinomed Biotech AG (VIE:MARI)

Marinomed Biotech AG (VIE:MARI) Could Be Riskier Than It Looks

Feb 03
Marinomed Biotech AG (VIE:MARI) Could Be Riskier Than It Looks

Marinomed Biotech AG (VIE:MARI) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Apr 22
Marinomed Biotech AG (VIE:MARI) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Marinomed Biotech AG's (VIE:MARI) Analyst Just Slashed This Year's Estimates

Sep 22
Marinomed Biotech AG's (VIE:MARI) Analyst Just Slashed This Year's Estimates

CEO Compensation Analysis

How has Andreas Grassauer's remuneration changed compared to Marinomed Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

-€15m

Sep 30 2024n/an/a

-€14m

Jun 30 2024n/an/a

-€14m

Mar 31 2024n/an/a

-€7m

Dec 31 2023n/an/a

-€6m

Sep 30 2023n/an/a

-€6m

Jun 30 2023n/an/a

-€6m

Mar 31 2023n/an/a

-€7m

Dec 31 2022€307k€222k

-€6m

Sep 30 2022n/an/a

-€5m

Jun 30 2022n/an/a

-€5m

Mar 31 2022n/an/a

-€6m

Dec 31 2021€300k€200k

-€6m

Sep 30 2021n/an/a

-€8m

Jun 30 2021n/an/a

-€7m

Mar 31 2021n/an/a

-€7m

Dec 31 2020€324k€200k

-€6m

Sep 30 2020n/an/a

-€6m

Jun 30 2020n/an/a

-€6m

Mar 31 2020n/an/a

-€6m

Dec 31 2019€440k€200k

-€7m

Sep 30 2019n/an/a

-€14m

Jun 30 2019n/an/a

-€15m

Mar 31 2019n/an/a

-€14m

Dec 31 2018€177k€177k

-€12m

Compensation vs Market: Insufficient data to establish whether Andreas's total compensation is reasonable compared to companies of similar size in the Austrian market.

Compensation vs Earnings: Andreas's compensation has increased whilst the company is unprofitable.

CEO

Andreas Grassauer (55 yo)

19.1yrs
Tenure
€307,200
Compensation

Mr. Andreas Grassauer, PhD, is a Co-Founder of Marinomed Biotechnology GmbH in 2006 and serves as its Chairman of Management Board and has been Chief Executive Officer since 2006. Mr. Grassauer has co-foun...

Leadership Team

NamePositionTenureCompensationOwnership
Andreas Grassauer
Co-Founder19.1yrs€307.20k7.4%
€ 1.7m
Eva Prieschl-Grassauer
Co-Founder19.3yrs€299.60k7.4%
€ 1.7m
Gabriele Ram
CFO & Member of Management Boardless than a yearno datano data
Stephanie Kniep
Head of Investor Relationsno datano datano data
19.1yrs
Average Tenure

Experienced Management: MARI's management team is seasoned and experienced (19.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Simon Nebel
Independent Chairman of Supervisory Board7.9yrs€65.30kno data
Brigitte Ederer
Independent Vice Chairwoman of the Supervisory Board6.5yrs€20.00kno data
Karl Mahler
Member of Supervisory Board.less than a yearno datano data
Balamurali Ambati
Member of Scientific Advisory Boardno datano datano data
Talin Barisani
Member of Scientific Advisory Boardno datano datano data
Julian Crane
Member of Scientific Advisory Boardno datano datano data
Ron Eccles
Member of Scientific Advisory Boardno datano datano data
Elisabeth Lackner
Independent Member of Supervisory Board2.9yrs€7.50kno data
4.7yrs
Average Tenure
62.5yo
Average Age

Experienced Board: MARI's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/21 19:38
End of Day Share Price 2025/05/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Marinomed Biotech AG is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vladimira UrbankovaErste Group Bank AG
Matthias GreiffenbergerGBC AG
Brigitte de Limagoetzpartners securities Limited